Breast Cancer
Conditions
Brief summary
Previous studies have shown that the FGF signaling pathway is closely related to endocrine therapy resistance in breast cancer, but there is not sufficient evidence for the combination of endocrine therapy and FGFR inhibitors. Anlotinib is a highly effective VEGFRs, FGFRs, PDGFRs multi-target tyrosine kinase inhibitor. Therefore, we conducted this single-arm, single-center phase II clinical study to evaluate the efficacy and the safety of anlotinib combined with fulvestrant in patients with metastatic HR+/HER2- breast cancer patients with FGFR mutation and resistance to aromatase inhibitor therapy, to provide new treatment options for these patients.
Detailed description
Endocrine therapy resistance is an unsolved problem in the treatment of HR+/HER2- metastatic breast cancer. Previous studies have shown that the FGF signaling pathway is closely related to endocrine therapy resistance in breast cancer, but there is not sufficient evidence for the combination of endocrine therapy and FGFR inhibitors. Anlotinib is a highly effective VEGFRs, FGFRs, PDGFRs multi-target tyrosine kinase inhibitor, which can effectively block the migration and proliferation of endothelial cells and reduce tumor microvessel density. The drug inhibits VEGFRs, FGFRs, PDGFRs to exert anti-angiogenesis effects and to achieve anti-tumor effects. Therefore, we conducted this single-arm, single-center phase II clinical study to evaluate the efficacy and the safety of anlotinib combined with fulvestrant in patients with metastatic HR-positive and HER2-negative breast cancer patients with FGFR mutation and resistance to aromatase inhibitor therapy, to provide new treatment options for these patients.
Interventions
DRUGFulvestrant plus Anlotinib
Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntarily sign the informed consent form; 2. 18-75 years old; 3. Women in any menstrual state, premenopausal or perimenopausal patients need to receive luteinizing hormone releasing hormone(LHRH) analogue; 4. Eastern Cooperative Oncology Group (ECOG) score \[0-1\] points; 5. The expected survival period is ≥12 weeks; 6. The diagnosis of invasive carcinoma by histology or cytology; Estrogen receptor (ER) positive (defined as \>1% nuclear ER staining); HER2 negative (defined as IHC 0 or 1+, or HER2(2+) with HER2 FISH detection no amplification); 7. Inoperable or recurrent/metastatic breast cancer patients with aromatase inhibitor treatment failure; 8. In the state of disease progression before enrollment; 9. There are FGFR mutations, which meets any of the following: ①Immunohistochemical method: any subtype of FGFR1/2/3/4 is positive; ② Gene detection results of tissue/blood sample shows that any subtype of FGFR1/2/3/4 has functional variation such as amplification, activating mutation or fusion; 10. Measurable disease according to RECIST version 1.1 or only bone metastasis; 11. Adequate hematological, hepatic function; 12. Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥50%.
Exclusion criteria
1. Have used Fulvestrant or its analogues; 2. History of other primary malignancy; 3. Allergic to the ingredients of Anlotinib Hydrochloride Capsules; 4. Previously received targeted drug therapy for FGFR; 5. Received chemotherapy within 4 weeks before enrollment; 6. Received endocrine therapy within 2 weeks before enrollment; 7. Patients with currently symptomatic brain or meningeal metastasis; 8. Concomitant diseases/conditions that is not controllable, and any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the patient's participation in this study; 9. Patients who cannot accept drugs orally; 10. Any other situation that the investigator judges cannot be enrolled in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical benefit rate (CBR) | 24 weeks | Response and progression will be evaluated using RECIST 1.1. Evaluation will occur every 3 months till progression or termination of the study. CBR is defined as ratio of participants who have stable disease for over 24 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 1 year | Time from the date of treatment to the date of tumor progression |
| Objective response rate (ORR) | 1 year | The proportion of best overall response of either complete or partial response. |
| Overall survival (OS) | 3 years | Time from the date of treatment to the date of death. |
| Number of Participants with Adverse Events | 1 year | Number of participants with adverse events related to the treatment. |
| The quality of life | 1 year | Using EORTC (European Organization for Research and Treatment of Cancer) QLQ-BR23 scale. The minimum and maximum values are 0 and 100, respectively. Higher scores mean better outcome. |
Countries
China
Contacts
Primary ContactFei Xu, MD
Backup ContactKuikui Jiang, MD
Outcome results
None listed